Investing.com - Ocuphire Pharma (NASDAQ: OCUP) reported third quarter EPS of $0.250, $0.47 better than the analyst estimate of $-0.220. Revenue for the quarter came in at $11.9M versus the consensus estimate of $3.03M.
Ocuphire Pharma's stock price closed at $2.830. It is down -30.640% in the last 3 months and up 4.810% in the last 12 months.
Ocuphire Pharma saw 0 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Ocuphire Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Ocuphire Pharma's Financial Health score is "excellent performance".
Check out Ocuphire Pharma's recent earnings performance, and Ocuphire Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar